File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Homologous and heterologous serological response to the N‐terminal domain of SARS‐CoV‐2 in humans and mice

TitleHomologous and heterologous serological response to the N‐terminal domain of SARS‐CoV‐2 in humans and mice
Authors
Issue Date2021
PublisherWiley for European Federation of Immunological Societies (EFIS). The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1521-4141
Citation
European Journal of Immunology, 2021, v. 51 n. 9, p. 2296-2305 How to Cite?
AbstractThe increasing numbers of infected cases of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses serious threats to public health and the global economy. Most SARS-CoV-2 neutralizing antibodies target the receptor binding domain (RBD) and some the N-terminal domain (NTD) of the spike protein, which is the major antigen of SARS-CoV-2. While the antibody response to RBD has been extensively characterized, the antigenicity and immunogenicity of the NTD protein are less well studied. Using 227 plasma samples from COVID-19 patients, we showed that SARS-CoV-2 NTD-specific antibodies could be induced during infection. As compared to the results of SARS-CoV-2 RBD, the serological response of SARS-CoV-2 NTD is less cross-reactive with SARS-CoV, a pandemic strain that was identified in 2003. Furthermore, neutralizing antibodies are rarely elicited in a mice model when NTD is used as an immunogen. We subsequently demonstrate that NTD has an altered antigenicity when expressed alone. Overall, our results suggest that while NTD offers a supplementary strategy for serology testing, it may not be suitable as an immunogen for vaccine development.
Persistent Identifierhttp://hdl.handle.net/10722/305699
ISSN
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 1.627
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLv, H-
dc.contributor.authorTsang, OTY-
dc.contributor.authorSo, RTY-
dc.contributor.authorW, Y-
dc.contributor.authorYuan, M-
dc.contributor.authorLiu, H-
dc.contributor.authorYip, GK-
dc.contributor.authorTeo, QW-
dc.contributor.authorLin, Y-
dc.contributor.authorLiang, W-
dc.contributor.authorWang, J-
dc.contributor.authorNg, WS-
dc.contributor.authorWilson, IA-
dc.contributor.authorPeiris, JSM-
dc.contributor.authorWu, NC-
dc.contributor.authorMok, CKP-
dc.date.accessioned2021-10-20T10:13:04Z-
dc.date.available2021-10-20T10:13:04Z-
dc.date.issued2021-
dc.identifier.citationEuropean Journal of Immunology, 2021, v. 51 n. 9, p. 2296-2305-
dc.identifier.issn0014-2980-
dc.identifier.urihttp://hdl.handle.net/10722/305699-
dc.description.abstractThe increasing numbers of infected cases of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses serious threats to public health and the global economy. Most SARS-CoV-2 neutralizing antibodies target the receptor binding domain (RBD) and some the N-terminal domain (NTD) of the spike protein, which is the major antigen of SARS-CoV-2. While the antibody response to RBD has been extensively characterized, the antigenicity and immunogenicity of the NTD protein are less well studied. Using 227 plasma samples from COVID-19 patients, we showed that SARS-CoV-2 NTD-specific antibodies could be induced during infection. As compared to the results of SARS-CoV-2 RBD, the serological response of SARS-CoV-2 NTD is less cross-reactive with SARS-CoV, a pandemic strain that was identified in 2003. Furthermore, neutralizing antibodies are rarely elicited in a mice model when NTD is used as an immunogen. We subsequently demonstrate that NTD has an altered antigenicity when expressed alone. Overall, our results suggest that while NTD offers a supplementary strategy for serology testing, it may not be suitable as an immunogen for vaccine development.-
dc.languageeng-
dc.publisherWiley for European Federation of Immunological Societies (EFIS). The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1521-4141-
dc.relation.ispartofEuropean Journal of Immunology-
dc.rightsSubmitted (preprint) Version This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Accepted (peer-reviewed) Version This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.titleHomologous and heterologous serological response to the N‐terminal domain of SARS‐CoV‐2 in humans and mice-
dc.typeArticle-
dc.identifier.emailSo, RTY: soty@hku.hk-
dc.identifier.emailPeiris, JSM: malik@hkucc.hku.hk-
dc.identifier.authorityPeiris, JSM=rp00410-
dc.identifier.authorityMok, CKP=rp01805-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/eji.202149234-
dc.identifier.pmid34089541-
dc.identifier.pmcidPMC8237060-
dc.identifier.scopuseid_2-s2.0-85108324388-
dc.identifier.hkuros327845-
dc.identifier.volume51-
dc.identifier.issue9-
dc.identifier.spage2296-
dc.identifier.epage2305-
dc.identifier.isiWOS:000664343900001-
dc.publisher.placeGermany-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats